AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: STEVE MITCHELL
WASHINGTON, Feb. 1 (UPI) -- Cellegy has granted a licensing agreement to CONRAD to research and develop its patented microbicides for the prevention of HIV, including Savvy, which is in phase 3, and a treatment dubbed "UC781," which is in phase 2.
The move appears to signal Cellegy's desire to get out of the HIV microbicide field, an area that big pharma has largely shied away from, preferring instead to focus on vaccines.
But experts said that microbicides could be available sooner than inoculations and could play a significant role in slowing down the spread of the HIV/AIDS epidemic.
"It's like the tortoise and the hare whether we'll have an effective microbicide before we have a…